Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
about
Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models.Emerging pharmacotherapies for neurodevelopmental disordersImplications of GABAergic Neurotransmission in Alzheimer's DiseaseTiagabine improves hippocampal long-term depression in rat pups subjected to prenatal inflammationGABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Allosteric modulation of GABA(A) receptor subtypes:effects on visual recognition and visuospatial working memory in rhesus monkeys [corrected].Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdalaTonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model.Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence.Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.Memory deficits induced by inflammation are regulated by α5-subunit-containing GABAA receptors.Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse ModelExtrasynaptic GABA(A) receptors: their function in the CNS and implications for disease.Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.Commentary on Ling et al. (2012): The PROMETA™ treatment does not reduce methamphetamine useDisinhibition, an emerging pharmacology of learning and memoryThe inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline.Neural oscillations during non-rapid eye movement sleep as biomarkers of circuit dysfunction in schizophrenia.GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.Mechanism of Allosteric Modulation of the Cys-loop Receptors.A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.An historical perspective on GABAergic drugs.GABAergic drugs and Alzheimer's disease.Context-Dependent Modulation of GABAAR-Mediated Tonic Currents.Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.Cinnamon Converts Poor Learning Mice to Good Learners: Implications for Memory Improvement.Developmental changes in GABAA tonic inhibition are compromised by multiple mechanisms in preadolescent dentate gyrus granule cells.Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.Therapeutics of Neurotransmitters in Alzheimer's Disease.GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.Dementia Enhances Inhibitory Actions of General Anesthetics in Hippocampal Synaptic Transmission
P2860
Q21129461-83EDDE92-CD3C-4847-8471-A1A0B3630F3BQ24619170-4EA291F1-BA4B-4CF1-84F5-2306D347D895Q26768593-F2D6C123-91C5-46E6-B6C6-D3CDAD4393C7Q27313386-DD59CAB7-AFA7-472B-AA52-82D590B25902Q30421260-99F04A2A-2773-44CD-BD34-4141C08875BEQ30429949-5E1FBE7E-5AAF-45CB-92FA-CE1F3D83A327Q30466591-13FE1392-8C80-4416-B793-65FED09BF991Q34006575-FCE985F5-44ED-4AB0-81D1-D44C207D55BAQ34157421-AB4A4730-F7A3-4AFE-BE6F-BB6E1FCA44BEQ34236634-91D0D960-859A-4729-A432-998838710489Q34702234-7377BEE8-DF6C-40C5-937B-1381A5762E55Q34809762-44B9EA82-C53B-4FBC-9F7D-0FB171295AB5Q35177041-B2C74A0A-C0A9-4195-9FF7-1392A1D3D625Q35343518-5C7A22D7-76D9-4D8D-87C3-8F11052230EEQ35418044-F88BA6C8-339F-4D1A-8EF1-C93019599866Q36101696-723A8B9A-10F8-4D05-88FD-9AA794FF4B92Q36243393-6D2A0BC1-9A0D-4225-B7D5-56D61118869AQ36806743-6928A3A2-939D-47D2-A897-D8E92BC1F452Q37635772-22EE92D2-8692-4009-8BF8-3FAA97734061Q37784829-5F1443DF-78BF-4B99-AC40-341D062B40E0Q38203026-8DD2F27C-F036-4CDD-A6A7-308AC5E40417Q38225536-8A5304B8-3ED4-4F99-88B7-D984F3B9C0E8Q38974419-15058DEF-467F-4556-8122-C91E27CB5BB8Q39456055-F62AEBFC-CFDA-4D89-8E13-B4FABE8E5EA4Q39768840-4A491D8D-F107-40D6-AF39-36CCD52EC4FEQ39768852-A4799124-D5C9-46BD-BE73-6CC207559E52Q40116043-0408115A-7D2E-473D-A20B-C97EF244E31CQ41574564-5EA76778-0392-42B5-B3B3-A696C990C7C9Q46661770-BB28CA4D-6E16-4510-90F5-9643D957F4D4Q47139484-F1F8D159-D942-46DC-ACF5-336BD1A16C84Q47666263-37E0E642-AE64-4575-8345-E04696838C85Q49672905-4FD0CC3D-BB23-458A-9F39-DF1E4354DB20Q53428761-3AAD2398-1B69-4245-9F97-D3CC3DCF0E70Q58690018-0DD2518F-A1FC-4D49-815B-E74B7B6958B5
P2860
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@en
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@nl
type
label
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@en
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@nl
prefLabel
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@en
Preclinical and clinical pharm ...... tive inverse agonist alpha5IA.
@nl
P1476
Preclinical and clinical pharm ...... ctive inverse agonist alpha5IA
@en
P2093
John R Atack
P356
10.1016/J.PHARMTHERA.2009.09.001
P50
P577
2009-09-19T00:00:00Z